Specifically, we provide evidence that the anthelmintics niclosamide and pyrvinium pamoate, and the anti‐fungal agent piroctone olamine may have the potential to be repurposed for the treatment of TBX2/TBX3‐driven cancers either as single agents or in combination with currently used chemotherapeutics. The gene discussed is TBX3; the disease is cancer.